Company / R&D per Share
NovoCure Ltd R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$2.07
FY2025
5-year range
$1.96 / $2.12
FY2021-FY2025
Trend
+5.7%
vs FY2024
Sector context
#44 of 103
Health Care
What the data says
At $2.07, NovoCure Ltd's r&d per share ranks #44 of 103 in the Health Care sector. R&D per Share has fluctuated over the past 10 years, ranging from $0.44 in FY2017 to $2.12 in FY2023.
Based on SEC 10-K filings.
2.07 in FY2025 with a 5-year CAGR of +9.3%.
Declined from $2.12 to $2.07 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +1.4%
- 5-Year CAGR
- +9.3%
- 10-Year CAGR
- -
Sector benchmark
#44 of 103 in Health CareTop 43% of 103This company $2.07 Sector average $2.13
▼
-3.0% below sector average
Key checks
Key Insights
- In FY2025, r&d per share increased 5.7% year-over-year.
- Ranks #44 out of 103 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2023.
- Lowest r&d per share in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score -0.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.07 | +5.7% |
| FY2024 | $1.96 | -7.8% |
| FY2023 | $2.12 | +7.1% |
| FY2022 | $1.98 | +0.8% |
| FY2021 | $1.97 | +48.3% |
| FY2020 | $1.33 | +56.6% |
| FY2019 | $0.85 | +49.9% |
| FY2018 | $0.57 | +29.2% |
| FY2017 | $0.44 | -11.6% |
| FY2016 | $0.49 | -84.8% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026